Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0006142 (
breast cancer
)
160,383
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The diagnostic value of mucin-like carcinoma-associated antigen (MCA) was compared to that of
carcinoembryonic antigen
(
CEA
) and/or CA 15.3 in patients with
breast cancer
. A total of 368 patients with
breast cancer
were studied, of whom 253 were free of metastases, whereas 94 had either skeletal or visceral metastases or diffuse metastatic disease. The diagnostic sensitivity of MCA proved to be comparable to that of CA 15.3 and superior to that of
CEA
in patients with metastatic breast cancer. In contrast, the specificity of MCA was superior to that of CA 15.3. Finally, the diagnostic sensitivity of each of the tested tumour markers, i.e. MCA,
CEA
and CA 15.3, could be improved by their combined use. We conclude that MCA, either alone or in combination with CA 15.3 and
CEA
, can improve the monitoring of disease progression in patients with metastatic breast cancer.
...
PMID:Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer. 275 62
Forty-three cases of male breast cancer treated in the past 3 decades, comprising 1.92% of total cases of
breast cancer
in both sexes during the same period, were analyzed. Local skin involvement occurred in half of the patients. 67.7% of the patients presented axillary lymph node metastases and 82.9% were in stage II and III. Non-infiltrative and infiltrative specific cancers were diagnosed in 2 cases each, and infiltrative non-specific in 39 cases. Retrospective determination of estrogen receptor (ER) and
carcinoembryonic antigen
(
CEA
) in 33 specimens revealed positive ER in 57.6% and positive
CEA
in 72.7%. The more advanced the clinical stage, the higher is the positive rate of ER. Cases with positive
CEA
usually carried a more invasive process and a poorer prognosis. Immunohistochemical investigation in male breast cancer patients was valuable in the selection of post-operative adjuvant endocrine therapy or chemotherapy. Postoperative rise in serum
CEA
in patients with positive
CEA
may indicate recurrence.
...
PMID:[Male breast cancer: clinical, pathologic and immunohistochemical study]. 277 23
Serum carbohydrate antigen (CA15-3) values were examined in 300 normal subjects in order to determine the standard value of this antigen. The clinical relevance of repeatedly assaying this marker in patients with or without recurrent breast cancer postoperatively was compared with assaying the serum
carcinoembryonic antigen
(
CEA
) values. The upper limit of CA15-3 was calculated as being 25.3 U/ml in the normal subjects and the distributions of CA15-3 values were not markedly different among the normal subjects, even if they had been selected according to sex or age. Moreover, no differences were observed among normal women who had been randomly selected according to the age distribution of the
breast cancer
patients. Thirty samples taken from the
breast cancer
patients postoperatively revealed values of higher than 25 U/ml and 73 samples showed lower levels. The serum
CEA
values were positive in 16 samples and negative in 85 samples. Although the accuracy of the
CEA
assay was about 10 per cent higher than that of the CA15-3 assay, its low positive rate was unsatisfactory for effective use in the breast clinic. The results of this study suggest that serum CA15-3 is not detectable unless there is a relatively large number of tumor cells. The higher false positive rate of the CA15-3 assay should therefore be considered as suggesting recurrence.
...
PMID:The clinical value of serum CA15-3 assay postoperatively in breast cancer patients. 277 26
Mucin-like cancer-associated antigen (MCA), a new tumor marker using the mouse monoclonal antibody b-12 is thought to be of value in the management of patients with
breast cancer
. In this study sera from 191 female patients with
breast cancer
(112 with progressive disease [PD] and 79 with no evidence of disease [NED]) were analyzed for MCA levels and compared with those of cancer antigen 15-3 (CA 15-3) in single determination and in combination with
carcinoembryonic antigen
(
CEA
) and tissue polypeptide antigen (TPA). A cut-off level of 14 U/ml for MCA seems to be more appropriate than the recommended 11 U/ml to distinguish between PD and NED in patients with
breast cancer
. Although there was a fairly good correlation of MCA to CA 15-3, MCA was inferior in sensitivity and specificity to CA 15-3. Patients with osseous metastases and those with more than one metastatic site showed higher MCA levels than patients with visceral or soft tissue metastases, a fact which was comparable to CA 15-3. Combining MCA and CA 15-3 resulted in a gain in specificity but marked loss of sensitivity. The combination of MCA and
CEA
results also in a loss of sensitivity whereas the combination of CA 15-3 and
CEA
showed an increased specificity and only a negligible loss of sensitivity. The combination of MCA with TPA is of little value in the follow-up of
breast cancer
, as is the combination of CA 15-3 with TPA. The combination of CA 15-3 with
CEA
can be still recommended for follow-up for early detection of metastases in
breast cancer
.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer. 279 51
Exponentially growing MCF7 human
breast cancer
cells were separated in Percoll gradients into six different fractions of increasing density (A to F). These fractions could be subcultured and were found to contain different cellular subpopulations as defined by the following criteria: ability to generate other cellular subpopulations; growth rate; DNA synthesis; and expression of estrogen receptors, ras oncogene-encoded protein p21, and
carcinoembryonic antigen
. One of the minor fractions (E), which contained about 5% of the total cell number, appeared to contain the stem cells, on the basis of the following criteria: (i) its ability to reproduce the other cellular subpopulations, (ii) its high rate of growth and DNA synthesis, and (iii) the inability of the other subpopulations to generate it. The most differentiated subpopulation appeared to be the densest one (F), since it was the slowest growing and appeared to be the end point of the other subpopulations.
...
PMID:Subpopulations of MCF7 cells separated by Percoll gradient centrifugation: a model to analyze the heterogeneity of human breast cancer. 282 56
Leukocyte alkaline phosphatase (LAP) scores in peripheral blood and plasma
carcinoembryonic antigen
(
CEA
) levels were determined in 208
breast cancer
patients with nonmetastatic disease. Patients were followed until clinical manifestations of metastases appeared. Then the LAP score and
CEA
level were analyzed in relation to the clinical appearance of metastases. Of the 208 patients studied, 58 developed metastases during the follow-up period. The LAP scores and
CEA
levels of this group of patients were compared to a control group of 60
breast cancer
patients who did not develop metastases. Of the two markers, LAP score seems to be considerably more useful in detecting metastatic disease.
...
PMID:Leukocyte alkaline phosphatase and carcinoembryonic antigen in breast cancer patients: clinical correlation with the markers. 291 42
The
carcinoembryonic antigen
(
CEA
) levels were determined in 42
breast cancer
patients at I, II, III, IV stages of TNM classification. Plasmatic preoperative
CEA
levels was under 6 ng/ml in the 94% of patients. The postoperative
CEA
levels of six patients who developed metastases during the follow-up was elevated in five cases, but the elevation never preceded the clinical and radiological diagnosis of metastases.
...
PMID:[Our experience with the diagnostic and prognostic unreliability of pre- and postoperative CEA in human breast cancer]. 293 Sep 84
A number of prognostic factors have emerged from a retrospective study of 83 patients with
breast cancer
associated with a solid intracerebral tumour (59%), or meningeal invasion (33%) or both (8%). The median survival was 4 months without significant difference between breast tumours and meningeal carcinomatosis. Women in pre-menopause at the initial diagnosis of
breast cancer
(P less than or equal to 0.05) or who were 50 years of age when the cerebral metastasis occurred (P less than or equal to 0.05) or who had only one metastasis (P less than or equal to 0.02) had a better prognosis. During meningeal carcinomatosis, CSF protein and
carcinoembryonic antigen
levels have no prognostic value. All patients with intracerebral tumour had been irradiated (40 Gy over 4 weeks). The tumour was removed whenever possible. Intrathecal or systemic chemotherapy and hormone therapy seem to be favourable prognostic factors. This would suggest that chemotherapy may increase the survival of patients with this type of
breast cancer
, but only randomized studies will demonstrate its true effectiveness.
...
PMID:[Survival and prognostic factors in cerebral metastases of breast cancer]. 294 46
We report here three cases of
breast cancer
with reactive multinucleated giant cells. The patients were among the 605 patients with
breast cancer
seen in the past 17 years at Tenri Hospital; the incidence of this variety of
breast cancer
was 0.5%. Enzyme histochemical and electron microscopic examination suggested that the giant cells were of histiocytic origin. However, results of immunohistochemical technique, S-100 protein, lysozyme, nonspecific cross-reacting antigen with
carcinoembryonic antigen
, alpha-1-antitrypsin, and alpha-1-antichymotrypsin, all currently used as markers of histiocytes, were negative. Because of the rarity of this variety of
breast cancer
, the biological significance of these unusual findings remains unknown.
...
PMID:Breast cancer with reactive multinucleated giant cells: report of three cases. 301 34
Saturable, high affinity binding sites for 3,5,3' triiodothyronine (T3) were identified in nuclei isolated from human tumors of various origins (breast cancers, other epitheliomas, sarcomas, tumors of the central nervous system). Nuclear T3 receptors were present in all samples of primary
breast cancer
(n = 93; average Cmax = 215 fmol/mg DNA) and in metastatic tissues originating from breast tumors. A significantly lower T3 binding capacity was found in non-tumor tissues, obtained from breast sites distal to the tumor (n = 30; average Cmax = 133 fmol/mg DNA; paired t-test: p less than 0.01). Specific nuclear T3 receptors were also present in other epitheliomas (n = 8; average Cmax = 432 fmol/mg DNA), sarcomas (n = 4; average Cmax = 297 fmol/mg DNA) and cerebral tumors (n = 13; average Cmax = 364 fmol/mg DNA. In 93 cases of
breast cancer
, a negative relationship was found between the nuclear T3 receptor level and the involvement of axillary lymph nodes (Pearson chi square value: p = 0.017). Except a possible relationship between the T3 receptor and the progesterone receptor concentrations, no significant correlation was observed between the nuclear T3 binding capacity in
breast cancer
samples and other clinical and biochemical parameters: age, tumour stage, histopathological grade, serum concentrations of thyroid hormones, TSH, CEA (
carcinoembryonic antigen
) and prolactin, cytoplasmic estrogen receptors. The presence of high affinity T3-binding sites in human tumor nuclei indicates that the thyroid hormones may play a role, at the cellular level, on the development of certain human cancers.
...
PMID:Nuclear thyroid hormone receptors in human cancer tissues. 301 22
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>